1. IDENTIFICATION OF THE SUBSTANCE/MIXTURE AND THE COMPANY/UNDERTAKING

Product Identifier

Material Name: TERRA-VET® 10

Trade Name:

Synonyms: Tetracycline Hydrochloride Soluble Powder

Chemical Family: Tetracycline derivative

Relevant Identified Uses of the Substance or Mixture and Uses Advised Against

Intended Use: Veterinary product

Restrictions on Use: Not for human use

Details of the Supplier of the Safety Data Sheet

Zoetis Inc.
100 Campus Drive, P.O. Box 651
Florham Park, New Jersey 07932 (USA)
Rocky Mountain Poison Control Center Phone: 1-866-531-8896
Product Support/Technical Services Phone: 1-800-366-5288

Zoetis Belgium S.A.
Mercuriusstraat 20
1930 Zaventem
Belgium

Emergency telephone number:
CHEMTREC (24 hours): 1-800-424-9300

Contact E-Mail: VMIPSrecords@zoetis.com

2. HAZARDS IDENTIFICATION

Appearance: Powder

Classification of the Substance or Mixture
Reproductive Toxicity: Category 1A

US OSHA Specific - Classification

Physical Hazard: Combustible Dust

EU Classification:
EU Indication of danger: Toxic to reproduction: Category 1
EU Symbol: T
EU Risk Phrases: R61 - May cause harm to the unborn child.

Label Elements

Signal Word: Danger

Hazard Statements: H360D - May damage the unborn child
May form combustible dust concentrations in air
Precautionary Statements:

- P201 - Obtain special instructions before use
- P202 - Do not handle until all safety precautions have been read and understood
- P210 - Keep away from heat/sparks/open flames/hot surfaces. - No smoking
- P240 - Ground/Bond container and receiving equipment
- P280 - Wear protective gloves/protective clothing/eye protection/face protection
- P308 + P313 - IF exposed or concerned: Get medical attention/advice
- P405 - Store locked up
- P501 - Dispose of contents/container in accordance with all local and national regulations

Other Hazards

Long Term:
Repeat-dose studies in animals have shown a potential to cause adverse effects on the developing fetus.

Known Clinical Effects:
May cause effects similar to those seen in clinical use including transient diarrhea, nausea and abdominal pain. Symptoms of chronic exposure to tetracyclines include redness and swelling of the skin, rash, chills, tooth discoloration, yellowing of the skin and eyes, nausea, vomiting, diarrhea, stomach pain, and chest pain. Individuals sensitive to this material or other materials in its chemical class may develop allergic reactions. Wheezing, asthma, low or high blood pressure, dizziness, lung congestion, blood changes (leukocytosis, atypical lymphocytes, toxic granulation of granulocytes and thrombocytopenia purpura), convulsion or shock may also occur. Drugs of this class may cause liver and kidney effects

Australian Hazard Classification (NOHSC):

Note:
This document has been prepared in accordance with standards for workplace safety, which requires the inclusion of all known hazards of the product or its ingredients regardless of the potential risk. The precautionary statements and warning included may not apply in all cases. Your needs may vary depending upon the potential for exposure in your workplace.

3. COMPOSITION/INFORMATION ON INGREDIENTS

<table>
<thead>
<tr>
<th>Hazardous Ingredient</th>
<th>CAS Number</th>
<th>EU EINECS/ELINCS List</th>
<th>EU Classification</th>
<th>GHS Classification</th>
<th>%</th>
</tr>
</thead>
<tbody>
<tr>
<td>Tetracycline Hydrochloride</td>
<td>64-75-5</td>
<td>200-593-8</td>
<td>Repr.Cat.1;R61</td>
<td>Repro. 1A (H360)</td>
<td>25*</td>
</tr>
</tbody>
</table>

Additional Information: *25 grams per pound

For the full text of the R phrases and CLP/GHS abbreviations mentioned in this Section, see Section 16

4. FIRST AID MEASURES

Description of First Aid Measures
Eye Contact:
Flush with water while holding eyelids open for at least 15 minutes. Seek medical attention immediately.
SAFETY DATA SHEET

Material Name: TERRA-VET® 10
Revision date: 11-Aug-2014
Version: 2.0

Skin Contact: Remove contaminated clothing. Flush area with large amounts of water. Use soap. Seek medical attention.

Ingestion: Never give anything by mouth to an unconscious person. Wash out mouth with water. Do not induce vomiting unless directed by medical personnel. Seek medical attention immediately.

Inhalation: Remove to fresh air and keep patient at rest. Seek medical attention immediately.

Most Important Symptoms and Effects, Both Acute and Delayed

For information on potential signs and symptoms of exposure, See Section 2 - Hazards Identification and/or Section 11 - Toxicological Information.

Breathing dust may worsen asthma symptoms.

Indication of the Immediate Medical Attention and Special Treatment Needed

Notes to Physician: None

5. FIRE-FIGHTING MEASURES

Extinguishing Media:
Extinguish fires with CO2, extinguishing powder, foam, or water.

Special Hazards Arising from the Substance or Mixture

Formation of toxic gases is possible during heating or fire.

Fire / Explosion Hazards:
During processing, dust may form explosive mixture in air. Fine particles (such as dust and mists) may fuel fires/explosions.

Advice for Fire-Fighters
During all fire fighting activities, wear appropriate protective equipment, including self-contained breathing apparatus.

6. ACCIDENTAL RELEASE MEASURES

Personal Precautions, Protective Equipment and Emergency Procedures
Avoid dust formation. Personnel involved in clean-up should wear appropriate personal protective equipment (see Section 8). Minimize exposure.

Environmental Precautions
Place waste in an appropriately labeled, sealed container for disposal. Care should be taken to avoid environmental release.

Methods and Material for Containment and Cleaning Up

Contain the source of the spill if it is safe to do so. Avoid generating airborne dust. Collect spilled material by a method that controls dust generation. Eliminate possible ignition sources (e.g., heat, sparks, flame, impact, friction, electricity), and follow appropriate grounding procedures. Use non-combustible absorbent material to wipe up spill and place in a sealed container for disposal. Clean contaminated surface thoroughly.

Additional Consideration for Large Spills:
Non-essential personnel should be evacuated from affected area. Report emergency situations immediately. Clean up operations should only be undertaken by trained personnel.

7. HANDLING AND STORAGE

Precautions for Safe Handling

ZT00035
7. HANDLING AND STORAGE

Eliminate possible ignition sources (e.g., heat, sparks, flame, impact, friction, electricity), and follow appropriate grounding and bonding procedures. Avoid contact with eyes, skin and clothing. Avoid breathing dust. Minimize dust generation and accumulation. Use with adequate ventilation. Avoid open handling. Use local exhaust ventilation or perform work under fume hood/fume cupboard. When handling, use appropriate personal protective equipment (see Section 8). Wash hands and any exposed skin after removal of PPE. Releases to the environment should be avoided. Review and implement appropriate technical and procedural waste water and waste disposal measures to prevent occupational exposure or environmental releases. Potential points of process emissions of this material to the atmosphere should be controlled with dust collectors, HEPA filtration systems or other equivalent controls.

Conditions for Safe Storage, Including any Incompatibilities

Storage Conditions: Store at room temperature in properly labeled containers. Keep away from heat, sparks and flames. Protect from light. Protect from moisture.

Storage Temperature: At or below 25°C (77°F)

Specific end use(s): No data available

8. EXPOSURE CONTROLS / PERSONAL PROTECTION

Control Parameters

Refer to available public information for specific member state Occupational Exposure Limits.

Tetracycline Hydrochloride

Zoetis OEL TWA 8-hr  500 µg/m³

Exposure Controls

Engineering Controls: Engineering controls should be used as the primary means to control exposures. Use process containment, local exhaust ventilation, or other engineering controls to maintain airborne levels below recommended exposure limits.

Personal Protective Equipment:

Hands: Wear impervious gloves as minimum protection.

Eyes: Wear safety glasses as minimum protection.

Skin: Wear impervious protective clothing when handling this compound.

Respiratory protection: If the applicable Occupational Exposure Limit (OEL) is exceeded, wear an appropriate respirator with a protection factor sufficient to control exposures to below the OEL.

9. PHYSICAL AND CHEMICAL PROPERTIES

Physical State: Powder
Odor: No data available.
Molecular Formula: Mixture
Color: No data available
Odor Threshold: No data available.
Molecular Weight: Mixture

Solvent Solubility: Slightly soluble: Alcohol Insoluble: Acetone
Water Solubility: No data available
Solubility: Soluble: Water
pH: No data available.
Melting/Freezing Point (°C): No data available.
Boiling Point (°C): No data available.
Partition Coefficient: (Method, pH, Endpoint, Value) No data available

Decomposition Temperature (°C): No data available.
Evaporation Rate (Gram/s): No data available.
Vapor Pressure (kPa): No data available.
SAFETY DATA SHEET

Material Name:  TERRA-VET® 10
Revision date: 11-Aug-2014

Vapor Density (g/ml): No data available
Relative Density: No data available
Viscosity: No data available

Flammability:
- Autoignition Temperature (Solid) (°C): No data available
- Flammability (Solids): No data available
- Flash Point (Liquid) (°C): No data available
- Upper Explosive Limits (Liquid) (% by Vol.): No data available
- Lower Explosive Limits (Liquid) (% by Vol.): No data available

10. STABILITY AND REACTIVITY

Reactivity: No data available
Chemical Stability: Stable under normal conditions of use.
Possibility of Hazardous Reactions
- Oxidizing Properties: No data available
- Conditions to Avoid: Keep away from heat, spark, flames and all other sources of ignition. Avoid dispersion as a dust cloud. Dust may form explosive mixture in air. Fine particles (such as dust and mists) may fuel fires/explosions.
- Incompatible Materials: As a precautionary measure, keep away from strong oxidizers
- Hazardous Decomposition Products: No data available

11. TOXICOLOGICAL INFORMATION

Information on Toxicological Effects
General Information: Toxicological properties of the formulation have not been investigated. The information included in this section describes the potential hazards of various forms of the active ingredient. The toxicities of the two materials can be expected to be similar.

Acute Toxicity: (Species, Route, End Point, Dose)

- **Oxytetracycline**
  - Mouse Oral LD50 > 5200 mg/kg
  - Rat Oral LD50 4800mg/kg
  - Mouse Subcutaneous LD50 > 3500mg/kg

- **Tetracycline Hydrochloride**
  - Rat Oral LD50 6443 mg/kg
  - Mouse Oral LD50 2759mg/kg
  - Rat Intravenous LD50 128mg/kg
  - Mouse Intravenous LD50 157mg/kg

Acute Toxicity Comments: A greater than symbol (>) indicates that the toxicity endpoint being tested was not achievable at the highest dose used in the test.

Repeated Dose Toxicity: (Duration, Species, Route, Dose, End Point, Target Organ)

- **Tetracycline Hydrochloride**
  - 14 Day(s) Rat Oral 50,000 ppm NOAEL No effects at maximum dose
  - 13 Week(s) Rat Oral 12,500 ppm NOAEL Liver, Bone

ZT00035
### 11. TOXICOLOGICAL INFORMATION

**Reproduction & Development Toxicity: (Duration, Species, Route, Dose, End Point, Effect(s))**

**Oxytetracycline**

<table>
<thead>
<tr>
<th>Test Type</th>
<th>Species</th>
<th>Route</th>
<th>Dose</th>
<th>End Point</th>
<th>Effect(s)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Embryo / Fetal Development</td>
<td>Rat</td>
<td>Oral</td>
<td>100 mg/kg/day</td>
<td>NOAEL</td>
<td>No effects at maximum dose</td>
</tr>
<tr>
<td>Embryo / Fetal Development</td>
<td>Rat</td>
<td>Intramuscular</td>
<td>41.5 mg/kg/day</td>
<td>NOAEL</td>
<td>No effects at maximum dose</td>
</tr>
<tr>
<td>Embryo / Fetal Development</td>
<td>Rabbit</td>
<td>Intramuscular</td>
<td>41.5 mg/kg/day</td>
<td>LOEL</td>
<td>Embryotoxicity</td>
</tr>
<tr>
<td>Embryo / Fetal Development</td>
<td>Dog</td>
<td>Intramuscular</td>
<td>20.75 mg/kg/day</td>
<td>LOEL</td>
<td>Embryotoxicity, Teratogenic,</td>
</tr>
</tbody>
</table>

**Tetracycline Hydrochloride**

<table>
<thead>
<tr>
<th>Test Type</th>
<th>Species</th>
<th>Route</th>
<th>Dose</th>
<th>End Point</th>
<th>Effect(s)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Fertility and Embryonic Development</td>
<td>Rat</td>
<td>Subcutaneous</td>
<td>240 mg/kg/day</td>
<td>LOAEL</td>
<td>Embryotoxicity</td>
</tr>
<tr>
<td>Fertility and Embryonic Development</td>
<td>Rat</td>
<td>Intramuscular</td>
<td>240 mg/kg/day</td>
<td>LOAEL</td>
<td>Fetotoxicity</td>
</tr>
<tr>
<td>Fertility and Embryonic Development</td>
<td>Mouse</td>
<td>Intraperitoneal</td>
<td>150 mg/kg/day</td>
<td>LOAEL</td>
<td>Developmental toxicity</td>
</tr>
</tbody>
</table>

**Genetic Toxicity: (Study Type, Cell Type/Organism, Result)**

**Oxytetracycline**

<table>
<thead>
<tr>
<th>Test Type</th>
<th>Organism</th>
<th>Result</th>
<th>Mutagenicity Type</th>
<th>Activation</th>
</tr>
</thead>
<tbody>
<tr>
<td>Bacterial Mutagenicity (Ames)</td>
<td>Salmonella</td>
<td>Negative</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Mammalian Cell Mutagenicity</td>
<td>Mouse Lymphoma</td>
<td>Positive with activation</td>
<td></td>
<td></td>
</tr>
<tr>
<td>In Vitro Chromosome Aberration</td>
<td>Chinese Hamster Ovary (CHO) cells</td>
<td>Negative</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Sister Chromatid Exchange</td>
<td>Chinese Hamster Ovary (CHO) cells</td>
<td>Negative</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Micronucleus</td>
<td>Mouse</td>
<td>Negative</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

**Tetracycline Hydrochloride**

<table>
<thead>
<tr>
<th>Test Type</th>
<th>Organism</th>
<th>Result</th>
<th>Mutagenicity Type</th>
<th>Activation</th>
</tr>
</thead>
<tbody>
<tr>
<td>Bacterial Mutagenicity (Ames)</td>
<td>Salmonella</td>
<td>Negative</td>
<td></td>
<td></td>
</tr>
<tr>
<td>In Vitro Chromosome Aberration</td>
<td>Chinese Hamster Ovary (CHO) cells</td>
<td>Negative</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Sex-Linked Recessive Lethal Test</td>
<td>Drosophila</td>
<td>Negative</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

**Carcinogenicity: (Duration, Species, Route, Dose, End Point, Effect(s))**

**Oxytetracycline**

- 103 Week(s) Rat Oral, in feed 2094 mg/kg/day NOEL Not carcinogenic

**Tetracycline Hydrochloride**

- 2 Year(s) Rat Oral, in feed 25,000 ppm NOAEL Not carcinogenic
- 2 Year(s) Mouse Oral, in feed 25,000 ppm NOAEL Not carcinogenic

**Carcinogen Status:**

None of the components of this formulation are listed as a carcinogen by IARC, NTP or OSHA.
12. ECOLOGICAL INFORMATION

Environmental Overview: Environmental properties have not been thoroughly investigated. Releases to the environment should be avoided. The aquatic toxicity studies below were conducted with a chemically related material.

Toxicity:

Aquatic Toxicity: (Species, Method, End Point, Duration, Result)

Oxytetracycline
Onchorhynchus mykiss (Rainbow Trout)  LC50  96 Hours  < 200 mg/L

Persistence and Degradability: No data available

Bio-accumulative Potential: No data available

Mobility in Soil: No data available

13. DISPOSAL CONSIDERATIONS

Waste Treatment Methods: Dispose of waste in accordance with all applicable laws and regulations. Member State specific and Community specific provisions must be considered. Considering the relevant known environmental and human health hazards of the material, review and implement appropriate technical and procedural waste water and waste disposal measures to prevent occupational exposure and environmental release. It is recommended that waste minimization be practiced. The best available technology should be utilized to prevent environmental releases. This may include destructive techniques for waste and wastewater.

14. TRANSPORT INFORMATION

The following refers to all modes of transportation unless specified below.

Not regulated for transport under USDOT, EUADR, IATA, or IMDG regulations.

15. REGULATORY INFORMATION

Safety, Health and Environmental Regulations/Legislation Specific for the Substance or Mixture

Canada - WHMIS: Classifications

WHMIS hazard class:
Class D, Division 2, Subdivision A
This product has been classified in accordance with the hazard criteria of the CPR and the SDS contains all of the information required by the CPR.
15. REGULATORY INFORMATION

Tetracycline Hydrochloride
  CERCLA/SARA 313 Emission reporting 1.0 %
  California Proposition 65 developmental toxicity initial date 1/1/91 internal use
  Inventory - United States TSCA - Sect. 8(b) Present
  Australia (AICS): Present
  EU EINECS/ELINCS List 200-593-8

16. OTHER INFORMATION

Text of R phrases and GHS Classification abbreviations mentioned in Section 3

Reproductive toxicity-Cat.1A; H360D - May damage the unborn child

Toxic to reproduction: Category 1

R61 - May cause harm to the unborn child.

Data Sources: The data contained in this MSDS may have been gathered from confidential internal sources, raw material suppliers, or from the published literature.

Reasons for Revision: Updated Section 6 - Accidental Release Measures. Updated Section 8 - Exposure Controls / Personal Protection. Updated Section 10 - Stability and Reactivity.

Prepared by: Toxicology and Hazard Communication
  Zoetis Global Risk Management

Zoetis Inc. believes that the information contained in this Safety Data Sheet is accurate, and while it is provided in good faith, it is without warranty of any kind, expressed or implied. If data for a hazard are not included in this document there is no known information at this time.

End of Safety Data Sheet

ZT00035